+ UnitedHealth Group earns its money in two economically distinct ways that management deliberately runs as one system: it collects fixed premiums to bear the medical-cost risk of roughly the entire spectrum of U.S. health coverage (UnitedHealthcare), and it sells the care delivery, pharmacy management and data-and-technology services that manage that same cost (Optum) — to itself and to competing p

+ At scale, UnitedHealth Group Incorporated (UNH) is the largest U.S. managed-care organisation, generating $447,567.0M of revenue in FY2025 — up from $184,840.0M a decade earlier, a near-uninterrupted compounding record that ended abruptly on the earnings line rather than the revenue line. Revenue continued to grow in FY2025, but split-adjusted diluted EPS fell to $13.23 from $15.51 and a FY2023 pe

+ | Report Date | 2026-08-13 |

+ | Diluted Weighted-Average Shares | 911M |

+ | Current Price | $405.59 |

+ | 12-Month Price Target | $374.16 |

+ *Source: Company SEC filings (10-K); see Appendix A.1.*

+ The company reports four segments across its two franchises. **UnitedHealthcare** is the risk-bearing insurance business, selling health benefits through Employer & Individual, Medicare & Retirement, and Community & State (Medicaid). Its economics are governed by a single variable — the spread between the premium it priced and the medical care ratio it actually realises — and in FY2025 that spread

+ **Optum Health** delivers care — primary, specialty and surgical — and, critically, moves providers off fee-for-service into fully accountable value-based arrangements in which Optum Health itself assumes medical-cost risk for a monthly premium. The single driver is therefore the same medical-cost trend that drives UnitedHealthcare, layered on top of Medicare Advantage funding: when both compress

+ **Optum Rx** is the pharmacy-care and PBM business — retail network, home delivery, specialty and infusion — whose driver is script volume and managed drug spend. It was the relative bright spot in FY2025, with both revenue and operating earnings rising on new client wins and higher volumes. **Optum Insight** sells data, analytics, technology and managed services to payers, providers and governmen

+ The segments are engineered to interlock: Optum Rx sells pharmacy management, Optum Health sells care delivery, and Optum Insight sells analytics and technology — all into UnitedHealthcare, priced at management's estimate of fair value and eliminated in consolidation. The intended flywheel is vertical integration that lowers total cost of care and captures the provider margin that a pure insurer w

+ UnitedHealth is, for practical purposes, a domestic U.S. enterprise, and it is actively completing its exit from what little international footprint remained. The company sold its Brazil operations (Amil) in the prior year and has agreed to dispose of its remaining South American businesses, an exit expected to close in the second half of 2026. The consequence is that residual foreign-currency exp

+ The most important fact about the leadership team is that almost all of it is new, installed simultaneously, and installed in the middle of the worst operating year in the company's modern history. Stephen Hemsley — a long-tenured former chief executive who ran the company through its earlier build-out — returned as Chief Executive Officer and Chair in May 2025; Wayne DeVeydt joined as Chief Finan

+ | FY2021 | $5,280.0M | $5,000.0M | $2,454.0M |

+ | FY2022 | $5,991.0M | $7,000.0M | $2,802.0M |

+ | FY2023 | $6,761.0M | $8,000.0M | $3,386.0M |

+ | FY2024 | $7,533.0M | $9,000.0M | $3,499.0M |

+ | FY2025 | $7,916.0M | $5,545.0M | $3,622.0M |

+ *Source: Company SEC filings (10-K); see Appendix A.1.*

+ For most of the past decade the capital-allocation story was simple and shareholder-friendly: a steadily rising dividend, consistent buybacks that reduced the split-adjusted diluted share count from 968M to 911M, and capital expenditure sized to support growth rather than merely replace assets. The FY2025 total-shareholder-return yield of 4.5% and a dividend payout ratio of 65.7% show a business t

+ **§1.6.1 Industry structure.** Managed-care returns are driven by three things: scale (spreading fixed administrative, network and technology costs over the largest possible membership, and negotiating leverage against providers), pricing and risk-selection skill (the actuarial ability to set a premium that covers realised cost), and privileged access to government programmes (Medicare Advantage b

+ **§1.6.2 Competitive advantages.** UnitedHealth's moat rests on three defensible pillars. First, scale: at $447,567.0M of revenue it is the largest U.S. health-benefits company, which confers unmatched fixed-cost absorption and provider-negotiating leverage. Second, vertical integration: the Optum-plus-UnitedHealthcare structure lets the company capture the care-delivery, pharmacy and analytics ma

+ **§1.6.3 Competitive vulnerabilities.** The moat has three real openings. The first is the one FY2025 exposed: scale and integration do not protect against a pricing error — if expected medical cost trend is set below realised trend, the fixed-premium model turns the company's size into a magnifier of the mistake rather than a buffer. The second is government-funding dependence: with CMS as the do

+ **§1.6.4 Verdict.** The competitive advantage is real and durable — scale and vertical integration are structural, and no domestic competitor matches the breadth of the Optum-plus-UnitedHealthcare system. But FY2025 is a warning that a wide moat is not the same as a stable margin: the model concentrates rather than diversifies medical-cost-trend risk, and it is levered to a single government payer

+ UnitedHealth is not a company whose risk is dominated by operating execution or the commodity cycle; the dominant risk is regulatory and legal, layered on top of a medical-cost cycle that turned against the entire managed-care industry in 2025 and a set of accounting judgments that, read together, show a company whose historical earnings cushions have thinned. The risks below are ranked by the wei

+ ### Risk 1 — A live federal investigation into Medicare, disclosed with no accrual and no estimable range

+ This is the risk that should lead the case. The Company faces an active Department of Justice action concerning its participation in the Medicare program, alongside long-running risk-adjustment coding scrutiny (RADV audits by CMS and the HHS Office of Inspector General), PBM investigations, antitrust history, and shareholder litigation. The forensic review flags the legal disclosure as a red item

+ The precise point matters. Under the accounting standard, recording no accrual means only that a loss is not both probable and reasonably estimable as management assesses it — it is emphatically **not** a statement that the exposure is small or unlikely. An analyst cannot size this from the filing, and the correct treatment is to carry it as a genuine, unquantified overhang rather than to read the

+ **Probability:** Medium (that the overhang persists and pressures the multiple is High; that it produces a financially material adverse judgment is Medium) | **Timeframe:** Immediate and ongoing | **Quantified potential impact:** Not quantifiable from the filing — no accrual and no range are disclosed; treated as a material unbounded overhang, not as immaterial.

+ ### Risk 2 — Medical-cost trend and the quality of reported earnings

+ Two red-flag findings converge here, and both bear on whether reported FY2025 earnings are a reliable base.

+ First, the **medical-cost estimate itself**. Medical costs payable is the Company's largest and most judgmental estimate — the auditor's single Critical Audit Matter (the IBNR reserve). In FY2025 the medical care ratio rose sharply while favorable prior-year reserve development, which had contributed meaningfully in each of the two prior years, collapsed to a token amount. This must be read correc

+ Second, the **composition of reported operating income**. Reported operating earnings are not a clean run-rate. A one-time gain on the deconsolidation of a business was booked *inside* operating costs — above the line, not below it — flattering the operating result, while a large Q4 "kitchen-sink" restructuring charge ran the other way and included a loss-contract reserve explicitly set for antici

+ The structural point worth making once: the cost cycle is **industry-wide** — every major managed-care peer reported an elevated medical loss ratio in FY2025 — so this is not a UnitedHealth-specific execution failure. But vertical integration does **not** hedge it. UnitedHealthcare (the insurer) and the Optum value-based care-delivery business are both long the same medical-cost-trend risk; a util

+ **Probability:** High (elevated trend and a thinner reserve cushion are current conditions, not tail events) | **Timeframe:** Immediate to 1–2 years | **Quantified potential impact:** Material — medical-cost estimation is the single largest swing factor in the earnings line, and the lost favorable-development cushion is a permanent reduction to the base rather than a timing item.

+ ### Risk 3 — Goodwill concentration and Optum Health impairment risk

+ Goodwill and other intangibles represent a very large share of total consolidated assets — the single largest category on the asset side. That in itself is not a red flag; the concern, and the reason the forensic review rates it red, is where the goodwill sits and when it was last tested. The largest goodwill balance sits in the Optum Health reporting unit, which swung to a full-year operating los

+ What an impairment would and would not do to the equity story: it would be a **non-cash** charge — it does not consume liquidity or trip debt covenants directly. But it would matter for a reason beyond the accounting entry: it would validate the market's existing doubt about the durability of the care-delivery assets that underpin the vertical-integration thesis, and, per the Company's own risk fa

+ **Probability:** Medium | **Timeframe:** 1–2 years (next annual test) | **Quantified potential impact:** Potentially large but non-cash; primarily a signaling and credit-rating risk rather than a cash-flow event. No headroom or discount-rate disclosure is provided to size it.

+ ### Risk 4 — Parent-company capital strain

+ This is the most under-appreciated risk in the case, because most readers assume group cash is fungible — and for a regulated insurance holding company it is not. UnitedHealth's parent is a holding company that funds its dividend, buybacks and debt service largely from dividends paid *up* to it by regulated insurance and HMO subsidiaries. Those subsidiaries must hold prescribed minimum statutory c

+ Why it matters to the financials: the engine that funds capital return is throttled precisely when a rising loss ratio raises required statutory capital, so the current dividend-plus-buyback pace is only partly self-funded from operations and is being supplemented with debt and intercompany borrowing — at a time when the rating agencies carry a negative outlook. The Q4 buyback halt is the first vi

+ **Probability:** Medium-High (the constraint is already visible in the filing) | **Timeframe:** Immediate to 1–2 years | **Quantified potential impact:** Constrains capital-return capacity and raises reliance on debt markets; a genuine limit on buyback pace rather than a solvency risk — group liquidity itself remains ample.

+ ### Risk 5 — Tax structure under direct IRS challenge

+ UnitedHealth's FY2025 effective tax rate fell to roughly half its prior-year level, driven by foreign tax benefits tied to an Ireland/Luxembourg structure, and amplified by the lower pre-tax base. The forensic review rates this red for a specific reason: the structure the low rate depends on is now under direct government challenge. Shortly after year-end, the Company received IRS Notices of Propo

+ Why it matters: a meaningful part of the FY2025 tax benefit — and the multi-year low cash-tax profile — rests on positions the IRS is now formally attacking. An adverse resolution would raise the go-forward effective and cash tax rate and could require back-year payments. Importantly for the rating, this risk is **already priced into the base case**: the valuation deliberately applies a materially

+ **Probability:** Medium | **Timeframe:** 1–3 years (tax controversies resolve slowly) | **Quantified potential impact:** Raises the sustainable tax rate above the reported level — but the valuation already normalizes to a higher rate, so this is largely reflected in the base case; incremental risk is back-year cash payments.

+ The picture is deliberately asymmetric: the downside risks above are more numerous and, in aggregate, weightier than the catalysts. That asymmetry is the case for a HOLD rather than a BUY. The catalysts below are genuine, but most are the *clearing* of existing overhangs rather than new sources of growth — and one of them, the discount-rate normalization, is as much a warning about the rating as a

+ ### Catalyst 1 — Medical-cost normalization and a medical-loss-ratio inflection

+ The most direct path to a re-rating is evidence that the medical-cost cycle has peaked and the loss ratio is turning down. Because the entire industry re-priced 2025 medical trend, a clean 2026 pricing cycle and moderating utilization would lift margins across the sector, and UnitedHealth has the scale and pricing sophistication to recover margin as contracts re-price. It would show up first in th

+ **Probability:** Medium | **Timeframe:** 1–2 years | **Monitoring trigger:** The quarterly medical care ratio trajectory and the sign and size of prior-year reserve development each quarter; favorable Medicare Advantage rate notices.

+ ---

+ ### Catalyst 2 — Risk-regime normalization and a lower discount rate (the two-way risk)

+ This must be stated plainly, because the discount-rate choice cuts both ways and is the single largest driver of fair value. The valuation intentionally uses a shorter-window beta that reflects the post-shock, high-volatility regime UnitedHealth has traded in since 2025, rather than the company's own long-run, pre-shock defensive beta. If the DOJ, IRS, goodwill and parent-capital overhangs clear a

+ **Probability:** Medium | **Timeframe:** 1–3 years | **Monitoring trigger:** Realized volatility and the stock's beta stabilizing back toward its long-run level; resolution of the legal, tax and capital overhangs that are keeping systematic risk elevated.

+ ---

+ ### Catalyst 3 — Resolution or de-escalation of the federal and tax overhangs

+ A favorable disposition of the DOJ risk-adjustment matter, a settlement of the IRS transfer-pricing challenge on manageable terms, or simply the removal of headline uncertainty would each lift a discrete discount on the equity. Because these overhangs are currently unquantified, their *resolution* — even at a modest cash cost — can be a positive for the multiple by converting an unbounded risk int

+ **Probability:** Low-Medium in any given year (these processes are slow) | **Timeframe:** 1–3 years | **Monitoring trigger:** Court disposition of the Special Master report; any first accrual or disclosed range; IRS settlement or assessment.

+ ---

+ ### Catalyst 4 — Restoration of capital return as a signal of parent liquidity recovery

+ The resumption of buybacks at a meaningful, self-funded pace — rather than the current modest, forward-contract-supported cadence — would be the clearest signal that upstream dividend capacity from the regulated subsidiaries has recovered and that the parent-capital strain in Risk 4 is easing. It matters less for the mechanical share-count reduction than as a confirmation that the underlying regul

+ **Probability:** Medium | **Timeframe:** 1–2 years | **Monitoring trigger:** Buyback pace returning to operating-cash-funded levels; upstream subsidiary-dividend capacity recovering; a stabilization of the rating-agency outlooks.

+ | 1 | DOJ Medicare action / legal overhang — no accrual, no range | Risk | M | Immediate | Active | Special Master disposition; any first accrual or disclosed range |

+ | 2 | Medical-cost trend & earnings quality (reserve cushion gone; one-time items in operating income) | Risk | H | Immediate–1–2y | Active | Quarterly medical care ratio; reserve-development sign |

+ | 3 | Optum Health goodwill impairment | Risk | M | 1–2y | Monitoring | FY2026 goodwill test on realigned basis; Optum Health recovery |

+ | 4 | Parent-company capital strain / upstream-dividend constraint | Risk | M/H | Immediate–1–2y | Active | Upstream dividend capacity vs statutory-capital needs; buyback pace |

+ | 5 | Tax structure under IRS transfer-pricing challenge | Risk | M | 1–3y | Active | Escalation to later years; settlement or assessment |

+ | 6 | Medical-cost normalization / MLR inflection | Catalyst | M | 1–2y | Monitoring | Quarterly medical care ratio; MA rate notices |

+ | 7 | Risk-regime normalization → lower discount rate (two-way) | Catalyst | M | 1–3y | Monitoring | Beta stabilizing to long-run level; overhangs clearing |

+ | 8 | Resolution of DOJ / IRS overhangs | Catalyst | L/M | 1–3y | Monitoring | Court disposition; IRS settlement |

+ | 9 | Restoration of self-funded capital return | Catalyst | M | 1–2y | Monitoring | Buyback pace; upstream-dividend recovery; rating outlooks |

+ *Source: Company SEC filings (10-K and subsequent 10-Q) and forensic footnote review; see Appendix A.1.*

+ These risks are not independent draws — they share a common root in the medical-cost cycle and compound through the regulated-subsidiary capital structure. The most damaging combination is a *simultaneous* medical-cost overshoot (Risk 2) and parent-capital strain (Risk 4): a rising loss ratio both depresses earnings and raises the statutory capital the subsidiaries must retain, which throttles the

+ The legal and tax overhangs (Risk 1 and Risk 5) compound the others through the discount rate rather than through cash flow. They are the reason the market currently prices UnitedHealth with a post-shock, elevated systematic-risk profile; while they remain live, they keep the cost of equity high and depress the multiple regardless of operating performance — and a settlement or judgment large enoug

+ UnitedHealth's material ESG and regulatory exposures are almost entirely of the "S" and "G" variety and are specific to the disclosures in this filing rather than generic. On the **regulatory and reimbursement** side, the government-programs book is the fulcrum: CMS has reduced or frozen Medicare Advantage benchmarks and may cut them further; the risk-adjustment model is being substantially revise

+ The **social license** dimension is unusually acute for this company and is disclosed as such: management explicitly acknowledges that the industry is subject to negative publicity, adverse media coverage and political debate over regulation that can depress the stock and invite scrutiny — a risk that became concrete during 2025. In response, the Company has launched a deliberate trust-and-transpa

+ On **governance**, three filing-specific items warrant attention. First, the year was marked by senior leadership turnover, with the return of the prior chief executive as Chair and CEO during a period of withdrawn guidance and a sharp share-price decline — a signal of instability at the top that an investor should weigh. Second, the corporate-practice-of-medicine structure consolidates physician

+ **Three-Statement Linkage Confirmation**:

+ - Net Income ties (Income Statement → Cash Flow Statement): confirmed — the FY2025 operating cash flow reconciliation opens with *total* net earnings including noncontrolling interests (pre-tax income of $14,697.0M less tax expense of $1,890.0M), which reconciles to the $12,056.0M attributable to shareholders once the noncontrolling-interest share is removed; no unexplained bridging item.

+ - Cash ties (Balance Sheet → Cash Flow Statement): confirmed — the closing cash and equivalents balance of $24,365.0M agrees between the balance sheet and the cash-flow statement.

+ - Retained Earnings reconciliation (Beg RE + NI - Dividends = End RE): confirmed within the ordinary buyback mechanic — opening retained earnings of $96,036.0M plus net income of $12,056.0M less dividends of $7,916.0M, then reduced by the portion of the $5,545.0M of repurchases charged to retained earnings once additional paid-in capital is exhausted, reconciles to the closing balance of $95,603.0

+ | YoY Growth | 11.8% | 12.7% | 14.6% | 7.7% | 11.8% |

+ | Cost of Goods Sold ($M) | $217,945.0M | $244,545.0M | $280,664.0M | $310,879.0M | $364,650.0M |

+ | **Gross Profit ($M)** | $69,652.0M | $79,617.0M | $90,958.0M | $89,399.0M | $82,917.0M |

+ | Gross Margin | 24.2% | 24.6% | 24.5% | 22.3% | 18.5% |

+ | Total OpEx excl. COGS ($M) | $45,682.0M | $51,182.0M | $58,600.0M | $57,112.0M | $63,953.0M |

+ | **EBITDA ($M)** | $27,073.0M | $31,835.0M | $36,330.0M | $36,386.0M | $23,325.0M |

+ | EBITDA Growth | 7.0% | 17.6% | 14.1% | 0.2% | -35.9% |

+ | Net Income Growth | 12.2% | 16.4% | 11.2% | -35.6% | -16.3% |

+ | EPS Growth | 12.8% | 17.1% | 12.7% | -35.0% | -14.7% |

+ *Source: UnitedHealth Group FY2025 Form 10-K, Consolidated Statements of Operations; figures per the FL model — see Appendix A.1–A.2.*

+ | Revenue | 11.4% | 11.7% | - |

+ | EBITDA | -9.8% | -1.6% | - |

+ | Net Income | -15.7% | -4.8% | - |

+ | Diluted EPS | -14.5% | -3.8% | - |

+ | FCF | -11.8% | -4.4% | - |

+ *Source: Company SEC filings (10-K); figures per the FL model — see Appendix A.1–A.2.*

+ **The revenue line held; everything beneath it broke.** The defining feature of UnitedHealth's FY2025 income statement is the divergence between a top line that behaved normally and a profit structure that did not. Revenue of $447,567.0M grew 11.8%, in line with the 11.7% five-year compound rate and a re-acceleration from FY2024's 7.7%. Growth was not driven by a single lever: management attribute

+ **The medical loss ratio is the central operating fact of FY2025.** Consolidated gross margin — which, for a managed-care insurer, is effectively the inverse of the blended medical-and-product cost ratio — compressed from 22.3% to 18.5%, extending a two-year slide from 24.5%. Management's own explanation is unusually candid: its pricing trends and member health-status assumptions for 2025 were "we

+ **The compression cascaded down the P&L and was amplified at every line.** EBIT collapsed to $18,964.0M from $32,287.0M — a steep single-year reduction in operating income — driving the EBIT margin from 8.1% to 4.2%. EBITDA fell to $23,325.0M (5.2% margin). Because the cost pressure sits in the largest line on the statement, a deterioration in the medical care ratio of the scale seen this year is

+ **Major movers — what actually moved the income statement:**

+ 1. **Medical cost trend / MLR deterioration (structural reset, cyclically amplified).** The single largest driver. The gap between priced-for and realized medical trend drove the gross-margin compression from 22.3% to 18.5% and is the root cause of the EBIT decline to $18,964.0M. Management warns these trends "may continue"; even with a 2026 recovery, the earnings base resets permanently lower bec

+ 2. **Collapse of favorable prior-year reserve development (RED flag — earnings quality, but read the direction carefully).** This is the most commonly misread item in the filing, and it points the opposite way to the usual insurer-under-pressure pattern. Favorable development of prior-year medical reserves collapsed relative to the prior year and fell further below the year before that, while a pr

+ 3. **Below-the-line disposal and FX losses — the FY2024/FY2025 distinction (YELLOW flag).** The two down years have *different* anatomies, and conflating them is an analytical error. In FY2024, EBIT was essentially flat ($32,287.0M versus $32,358.0M), yet net income fell -35.6% — the damage was almost entirely *below* the operating line, driven by the large Brazil (Amil) disposal loss, much of it

+ 4. **The effective tax rate cushioned net income — and is not durable (RED flag).** Net income of $12,056.0M fell only -16.3%, far less than the operating-income decline from $32,287.0M to $18,964.0M, because the effective tax rate fell to just 12.9% from 24.1% — the tax line absorbed much of the operating shock. This is not an advantage to extrapolate. The low rate leaned on foreign (Ireland/Luxe

+ 5. **Q4 "kitchen-sink": offsetting one-offs inside operating income (RED flag — quality of earnings).** Reported EBIT of $18,964.0M is *not clean*. It is flattered by a large one-time gain on the deconsolidation of a business — booked *inside* operating costs, not below the line — together with net portfolio-divestiture gains concentrated at Optum Rx; and it is simultaneously depressed by a substa

+ **Quality of earnings.** The forensic screens corroborate that this is a genuine operating reset rather than an accounting event: the Beneish M-Score reads clean and Sloan accruals sit in the normal range for FY2025, and the auditor issued an unqualified opinion with the sole Critical Audit Matter being medical IBNR — precisely the estimate flagged above. The caution is not fabrication; it is that

+ **⚠ Items to Watch.** If the EBIT margin fails to recover from 4.2% back toward even FY2024's 8.1%, the "cyclical reset" thesis weakens toward "structural impairment," and the earnings-power base assumed in Section 6 would need to be lowered. If favorable prior-year reserve development does not normalize toward a positive contribution — or if a further premium-deficiency reserve is booked — the re

+ | Inventory ($M) | $2,900.0M | $3,500.0M | — | — | — |

+ *Source: UnitedHealth Group FY2025 Form 10-K, Consolidated Balance Sheets; figures per the FL model — see Appendix A.1–A.2.*

+ **Asset composition: an acquisition-built, intangible-heavy balance sheet.** Total assets reached $309,581.0M, but the striking feature is what dominates them. Goodwill stands at $110,499.0M — the largest single line on the asset side and the accumulated cost of a decade of Optum-led acquisition, up from $75,795.0M in FY2021; including other intangibles, the acquired-asset base is larger still and

+ **Goodwill concentration is now a live impairment question (RED flag).** The concern is not the size of goodwill per se but its concentration in the weakest reporting unit. Optum Health — which carries the largest goodwill balance in the group — swung to a full-year operating loss in FY2025 and lost members, yet management asserts all reporting units had fair values "substantially in excess" of ca

+ **Leverage: the deterioration is denominator-driven, not a debt binge.** Net debt rose to $54,024.0M from $51,592.0M, and Net Debt/EBITDA jumped to 2.3x from 1.4x — its highest in the period and up from 1.0x in FY2023. But this is a classic analytical trap: total debt was essentially flat year-on-year ($78,389.0M versus $76,904.0M), and Debt/Equity barely moved at 0.8x. The leverage-ratio spike is

+ **But the parent company is genuinely capital-constrained (RED flag).** The comfort at the *group* level does not extend to the *parent*. UnitedHealth is a holding company that depends on dividends upstreamed from its regulated insurance subsidiaries, and that engine throttled sharply in FY2025: upstream subsidiary dividends fell sharply, the parent had to push capital *down* into the subsidiaries

+ **Working capital: stable float, but one screen misfires and one flag flatters the optics.** The cash conversion cycle remains structurally negative (-18 days), the normal and favorable insurer profile. DSO improved modestly to 19 days — but this improvement is partly artificial: in FY2025 the company launched a new receivables-financing (factoring) facility and sold receivables during the year, w

+ **⚠ Items to Watch.** If Net Debt/EBITDA fails to retrace from 2.3x back toward the 1.0x range of FY2023 as EBITDA recovers — or rises further because capital returns stay debt-funded while upstream dividends remain throttled — it would confirm the leverage problem is structural rather than a denominator artifact and would pressure the Negative rating outlooks toward downgrade. A goodwill impairme

+ | — Depreciation & Amortization ($M) | $3,103.0M | $3,400.0M | $3,972.0M | $4,099.0M | $4,361.0M |

+ | Capital Expenditures ($M) | $2,454.0M | $2,802.0M | $3,386.0M | $3,499.0M | $3,622.0M |

+ | Dividends Paid ($M) | $5,280.0M | $5,991.0M | $6,761.0M | $7,533.0M | $7,916.0M |

+ | Share Repurchases ($M) | $5,000.0M | $7,000.0M | $8,000.0M | $9,000.0M | $5,545.0M |

+ *Source: UnitedHealth Group FY2025 Form 10-K, Consolidated Statements of Cash Flows; figures per the FL model — see Appendix A.1–A.2.*

+ **Operating cash flow fell with earnings — and looks better than it is.** Operating cash flow declined to $19,697.0M from $24,204.0M, and free cash flow fell to $16,075.0M (3.6% of revenue), the weakest FCF margin of the period. Management attributes the decline primarily to lower net earnings, partly offset by working-capital movements, the sale of receivables and the non-recurrence of the 2024 c

+ **CapEx is disciplined and steady — this is not where cash went.** Capital expenditure of $3,622.0M held at roughly 0.8% of revenue, consistent with the entire period, and CapEx/D&A sat at 0.8x. A CapEx/D&A ratio persistently *below one* tells the reader this is a capital-light services-and-insurance model whose reinvestment runs through acquisitions and capitalized software rather than physical p

+ **Capital-allocation waterfall: the mix is now under strain.** Across the five-year window, free cash flow has overwhelmingly been returned to shareholders through a rising dividend and large buybacks, with acquisitions funded largely from a combination of cash flow and incremental debt. The FY2025 inflection is telling: the dividend rose again to $7,916.0M — management protected the dividend — bu

+ **⚠ Items to Watch.** If FCF fails to recover from $16,075.0M back toward the $20,705.0M+ range, dividends alone (already $7,916.0M) would absorb a large share of free cash flow, leaving little organic room for buybacks and forcing continued reliance on debt to sustain the total payout. A sustained fall in FCF conversion *after* adjusting for the factoring facility — rather than the flattered 133.

+ | ROIC | 20.2% | 21.4% | 21.6% | 18.2% | 11.3% |

+ | ROE | 25.2% | 26.9% | 26.9% | 15.9% | 12.9% |

+ | ROA | 8.4% | 8.8% | 8.6% | 5.0% | 4.0% |

+ *Source: Company SEC filings (10-K); figures per the FL model — see Appendix A.1–A.2.*

+ **Returns compressed to the point where the spread over the cost of capital has narrowed sharply.** Return on invested capital fell to 11.3% in FY2025, down sharply from 18.2% a year earlier and well below the FY2021–FY2023 range of 20.2% to 21.6%. Return on equity fell to 12.9% and return on assets to 4.0%. This is the most important long-run signal in the section: for most of the past decade Uni

+ **DuPont decomposition: margin is the whole story; leverage is quietly rising.** Decomposing FY2025 ROE of 12.9% into its drivers, net margin was 2.7%, asset turnover 1.47x, and the equity multiplier 3.25x. The swing factor is unambiguously **net margin**: asset turnover has been remarkably stable — 1.40x in FY2021 versus 1.47x in FY2025, and the equity multiplier has drifted only gradually higher

+ | **Z-Score** | **2.18** | **2.10** | **2.03** |

+ | Zone | Grey | Grey | Grey |

+ *Source: Company SEC filings (10-K); figures per the FL model — see Appendix A.1–A.2.*

+ **Interpret the Z-score with the model's limitations front of mind.** The Altman Z-Score reads 2.03 for FY2025, in the "Grey" zone, having drifted down from 2.18 in FY2023 — a mild, consistent deterioration driven almost entirely by the X3 component (EBIT/Total Assets), which fell from 0.118 to 0.061 as operating income collapsed. The score here is computed on the **private-firm Z′ coefficients**

+ All inputs to the WACC are verified market data (from market-researcher output) or approved assumptions. Computed metrics are marked accordingly. The single most consequential judgment in this entire valuation is not a cash-flow assumption but the discount rate — and within the discount rate, the beta window. It is set out explicitly below rather than presented as a model output, because it, more

+ | Risk-Free Rate (10Y UST) | 4.70% | US Treasury daily yield curve |

+ | Equity Risk Premium | 4.23% | Damodaran implied ERP |

+ | Beta (Levered) | 1.29 | Raw 24-month monthly beta (see below) — not relevered |

+ | Size Premium | 0.00% | Not applied — mega-cap |

+ | Company-Specific Risk Premium | 0.00% | Not applied — see rationale below |

+ | **Cost of Equity (Ke)** | **10.16%** | CAPM: Rf + β × (ERP + CRP) |

+ *Source: FL valuation model (Valuation sheet); market inputs per Appendix A.1 (Tier 2/3).*

+ The cost of equity of 10.16% rests decisively on one input: beta. At this capital structure the equity weight is roughly seven-eighths of the total, so Ke — and through it the WACC — is dominated by the beta assumption; the risk-free rate and equity risk premium are effectively fixed market observables, leaving beta as the only material lever.

+ **The beta decision, and why the model's automatic figure was overridden.** The pipeline's automatic beta, measured from five years of monthly returns, was 0.63. That number describes a defensive, low-volatility UnitedHealth — a company whose share price historically moved far less than the market — and it implies a materially lower cost of equity and a fair value well *above* the current price. W

+ We also rejected the *shorter* window. A trailing twelve-month beta would be far higher still, but it is too short to be statistically reliable and it over-weights company-specific shocks — the federal investigation, the executive transition, the reserve disclosure — that are idiosyncratic events a beta is not meant to price as systematic market risk. The 24-month window is the deliberate middle:

+ **Why no company-specific or country risk premium.** The company-specific risk premium is held at 0.00% and no country premium is applied. UnitedHealth is US-domiciled with essentially all of its revenue earned domestically, so there is no country add-on to make. More importantly, the company's genuine idiosyncratic overhangs — the Department of Justice Medicare investigation, the March-2026 IRS t

+ | Marginal Tax Rate | 23.00% |

+ | **After-tax Cost of Debt** | **3.97%** |

+ *Source: FL valuation model (Valuation sheet); market inputs per Appendix A.1 (Tier 2/3).*

+ The pre-tax cost of debt of 5.15% is derived directly from the workbook as FY2025 interest expense over average total debt across the FY2024–FY2025 year-ends. It is consistent with the company's credit profile: the debt is well-laddered with no near-term maturity wall, all covenants are in compliance, and the average portfolio rating sits in the double-A band, so a blended pre-tax cost at this lev

+ | Equity Weight (market value) | 87.1% |

+ | Debt Weight (market value) | 12.9% |

+ | **WACC** | **9.36%** |

+ *Source: FL valuation model (Valuation sheet); market inputs per Appendix A.1 (Tier 2/3).*

+ At 87.1% equity and 12.9% debt on a market-value basis, the capital structure is only modestly leveraged, and because equity carries the overwhelming weight, the WACC of 9.36% is almost entirely a function of the cost of equity — and therefore of the beta window chosen above. This is the crux of the whole exercise: the dominant sensitivity is not a marginal move in Ke but the choice of beta itself

+ The valuation is anchored on a five-year explicit discounted-cash-flow projection plus a terminal value, with the terminal value computed two ways — a perpetuity-growth calculation and an exit EV/EBITDA multiple — and the perpetuity method selected for the base case (the two are reconciled in 4.2.3). Three scenarios are carried: Base, Bear and Bull. The Bear and Bull cases apply the standard symme

+ | Revenue Growth — each year | Base - 2pp | 0.5% (Y1) → 5.5% (Y5) | Base + 2pp |

+ | EBITDA Margin — each year | Base - 1pp | 7.2% (Y1) → 7.8% (Y5) | Base + 1pp |

+ | CapEx / Revenue — each year | unchanged | 0.9% (Y1) → 0.9% (Y5) | unchanged |

+ | D&A / Revenue — each year | unchanged | 1.0% (Y1) → 1.0% (Y5) | unchanged |

+ | Effective Tax Rate | unchanged | 23.0% | unchanged |

+ | Terminal Growth Rate | Base - 0.5pp | 3.0% | Base + 0.5pp |

+ | Exit EV/EBITDA Multiple | 11.0x | 11.0x | 11.0x |

+ | WACC | 9.36% | 9.36% | 9.36% |

+ *Source: FL valuation model (Valuation sheet); market inputs per Appendix A.1 (Tier 2/3).*

+ *Note: Bear and Bull use the standard adjustments above (per the valuation-agent methodology), applied to every projection year. The resulting fair values appear in Section 6.2 ($258.80 / $521.23).*

+ **The earnings base — why it is neither the FY2025 print nor a doubled first half.** This is the second-most-important choice in the model after the beta, and it deserves to be walked through rather than asserted. Reported FY2025 EBIT of $18,964.0M — down sharply from $32,287.0M the prior year — is a genuine trough, but it is also a contaminated one, and it is contaminated in both directions at on

+ Nor can the base simply be the first half of 2026 annualised. H1-2026 earnings were inflated by a swing back to favorable prior-year reserve development, which must be stripped before the half can be extrapolated, and the second half of a managed-care year is seasonally weaker as the medical cost ratio rises through the year. The model therefore builds the projection off FY2025 actual revenue of $

+ **Revenue growth path.** The base path runs from near-flat growth of 0.5% in Year 1 to 5.5% by Year 5, and it is deliberately set below the company's own historical growth rate. Year 1 is essentially flat because underlying membership and medical-trend growth are offset by the drag from the South American exit and portfolio pruning; Year 2 of 3.0% reflects the anniversary of those divestitures and

+ **Margin path.** The EBITDA margin recovers from 7.2% in Year 1 to a terminal 7.8% — a *partial* recovery, held deliberately below the pre-shock peak. Two structural reasons drive that ceiling. First, the favorable prior-year reserve-development cushion that historically added several tenths of a point to margin every year is permanently gone; treating its return as recurring would be a bull assum

+ **Forward tax rate.** The projection uses a forward effective tax rate of 23.0%, well above the rate UnitedHealth actually reported in FY2025. This is a considered normalization, not a conservatism reflex. The reported rate leaned heavily on Ireland and Luxembourg tax structures that are now under direct IRS challenge — the company received Notices of Proposed Adjustment in March 2026 targeting ex

+ **Terminal growth rate.** The terminal growth rate of 3.0% is framed against long-run US nominal GDP of roughly four percent, which functions as a hard ceiling; 3.0% sits comfortably below it. It is set above pure inflation to reflect the genuine structural tailwinds — an aging population, rising Medicare Advantage penetration, and healthcare's growing share of GDP — but below the nominal-GDP ceil

+ | Revenue ($M) | $447,567.0M | $449,804.8M | $463,299.0M | $486,463.9M | $513,219.4M | $541,446.5M |

+ | EBITDA ($M) | — | $32,385.9M | $34,284.1M | $36,971.3M | $40,031.1M | $42,232.8M |

+ | EBIT ($M) | — | $27,887.9M | $29,651.1M | $32,106.6M | $34,898.9M | $36,818.4M |

+ | NOPAT ($M) | — | $21,473.7M | $22,831.4M | $24,722.1M | $26,872.2M | $28,350.1M |

+ | Unlevered FCF ($M) | — | $22,137.2M | $23,458.9M | $25,336.0M | $27,508.2M | $29,021.2M |

+ | PV of UFCF ($M) | — | $20,242.4M | $19,614.9M | $19,371.2M | $19,231.8M | $18,552.9M |

+ *Source: FL valuation model (Valuation sheet); market inputs per Appendix A.1 (Tier 2/3).*

+ The unlevered free cash flow path is characteristically capital-light: with capex and D&A each only a small fraction of revenue, NOPAT converts to unlevered free cash flow at a high rate, and working capital is set to a small deliberate consumption rather than crediting the insurer's float as a source of cash — a conservative choice that also sidesteps the fact that reported operating cash flow is

+ | Sum of PV of UFCFs ($M) | $97,013.3M |

+ | Terminal Value — Perpetuity Growth ($M) | $469,961.5M |

+ | Terminal Value — Exit Multiple ($M) | $464,561.1M |

+ | Selected Terminal Value ($M) | $469,961.5M |

+ | PV of Terminal Value ($M) | $300,441.7M |

+ | Terminal Value as % of Enterprise Value | 76% |

+ | **Enterprise Value ($M)** | **$397,455.0M** |

+ | Less: Minority Interest ($M) | $7,588.0M |

+ | **Equity Value ($M)** | **$335,843.0M** |

+ | Shares Outstanding (M — current count used in the per-share bridge) | 897.6 |

+ | **DCF Fair Value / Share (Base)** | **$374.16** |

+ | Upside / Downside vs. Current Price | -7.8% |

+ *Source: approved valuation assumptions written to the Valuation sheet of the workbook; every figure traceable via lineage.json.*

+ The two terminal-value methods corroborate each other closely: the perpetuity-growth calculation of $469,961.5M and the exit-multiple calculation of $464,561.1M sit within a few percent of one another, which is reassuring given how much of the valuation rides on the terminal leg. The perpetuity method is selected for the base case at $469,961.5M. After deducting net debt of $54,024.0M and minority

+ Because roughly three-quarters of the enterprise value sits in the terminal value, the fair value is highly sensitive to both the discount rate and the terminal growth rate. The grid below isolates the perpetuity-growth terminal leg, varying WACC and terminal growth. Its bolded central cell corresponds to the base assumptions, and because the base case uses the pure perpetuity method (not a blend)

+ **WACC × Terminal Growth Rate → DCF Fair Value (Perpetuity Method)**

+ | WACC (down) / TGR (across) | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |

+ | 8.4% | 389.5 | 420.9 | 458.3 | 503.3 | 558.6 |

+ | 8.9% | 355.4 | 381.7 | 412.6 | 449.3 | 493.4 |

+ | **9.4%** | 325.9 | 348.3 | **374.2** | 404.5 | 440.5 |

+ | 9.9% | 300.2 | 319.3 | 341.3 | 366.7 | 396.5 |

+ | 10.4% | 277.5 | 294.1 | 312.9 | 334.5 | 359.5 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ The grid geography is straightforward: WACC rises down the rows and terminal growth rises across the columns, so the richest values sit in the top-right corner (lowest discount rate, highest terminal growth) and the poorest in the bottom-left. Reading across the base WACC row, the perpetuity leg reaches the current price of $405.59 only in the upper-right region of that row — that is, at a termina

+ **WACC × Exit EV/EBITDA Multiple → DCF Fair Value (Exit-Multiple Method)**

+ | WACC (down) / Exit EV-EBITDA (across) | 7.0x | 9.0x | 11.0x | 13.0x | 15.0x |

+ | 8.4% | 262.9 | 325.9 | 388.9 | 451.8 | 514.8 |

+ | 8.9% | 256.4 | 317.9 | 379.5 | 441.0 | 502.6 |

+ | **9.4%** | 250.0 | 310.2 | **370.3** | 430.5 | 490.6 |

+ | 9.9% | 243.8 | 302.6 | 361.4 | 420.2 | 479.0 |

+ | 10.4% | 237.8 | 295.2 | 352.7 | 410.2 | 467.7 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ The exit-multiple grid tells the same story from the other terminal method and corroborates it: at the base WACC and the selected mid-cycle multiple, the exit-method fair value lands within a few dollars of the perpetuity result, confirming that the base-case conclusion does not depend on which terminal convention is chosen. What it *does* depend on — visibly, in both grids — is the row the reader

+ > **Read this section differently than usual.** FY2025 was a synchronised cyclical trough for the entire managed-care group: every one of the four peers reported an elevated medical-loss ratio, and every earnings-based multiple in the tables below is therefore struck on depressed profit. A low peer P/E this year is not evidence of "cheap," and a high one is not evidence of "expensive." For that re

+ The comparable set — CVS Health, Elevance Health, Cigna and Humana — is the natural US managed-care and health-services cohort: the only other scaled, publicly listed entities that combine an insured risk book with adjacent pharmacy, care-delivery or health-services operations. All four file 10-Ks under US GAAP with a 31 December fiscal year-end, so there is no accounting-standard or period-alignm

+ The critical point for the reader is that these four are not interchangeable, and treating them as a single "insurer" bucket would mislead:

+ - **Elevance** is the cleanest structural comparable — Blue-branded health plans plus the smaller Carelon services arm — and is the primary like-for-like benchmark for UnitedHealthcare. Its Carelon business is far smaller than UNH's Optum, so where UNH's consolidated economics beat Elevance, that gap partly reflects Optum rather than superior health-plan underwriting.

+ - **CVS Health** is a retail-pharmacy, pharmacy-benefit and insurance conglomerate; premiums are only about a third of revenue, so its consolidated margins are structurally, not competitively, lower — and its FY2025 earnings-based multiples are further distorted by a large goodwill impairment (see 5.7).

+ - **Cigna** is pharmacy-benefit-led: the overwhelming majority of revenue is Evernorth pharmacy throughput, with insurance premiums a small minority. Its thin headline margins are a revenue-mix artifact of low-margin drug pass-through, not evidence of weakness.

+ - **Humana** is Medicare-Advantage-concentrated, so its cost cycle has a different shape from UNH's more diversified book, and its FY2025 free cash flow is distorted by one-off working-capital timing.

+ | CVS Health Corporation | CVS | NYSE | 10-K | US GAAP | December | Retail-pharmacy + PBM + insurer; consolidated margins not comparable to a pure health plan; FY2025 earnings depressed by a goodwill impairment |

+ | Elevance Health, Inc. | ELV | NYSE | 10-K | US GAAP | December | Closest structural comparable; Blue-branded plans + smaller Carelon services arm |

+ | The Cigna Group | CI | NYSE | 10-K | US GAAP | December | PBM-led (Evernorth); insurance a minority of revenue; low margins are a mix artifact |

+ | Humana Inc. | HUM | NYSE | 10-K | US GAAP | December | Medicare-Advantage-concentrated; FY2025 FCF depressed by working-capital timing |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ Before reading a single margin below, anchor on the one fact that governs the whole table: **FY2025 was an industry-wide managed-care margin shock.** Elevated Medicare Advantage and Medicaid utilisation lifted every company's medical-loss ratio simultaneously and compressed every company's margin. The absolute levels here are a shared trough, not a set of durable competitive differentials — so the

+ | Metric | UnitedHealth | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | Gross Margin | 18.5% | 13.8% | 14.9% | 9.3% | 14.5% |

+ | EBITDA Margin | 5.2% | 2.3% | 4.9% | 4.4% | 2.7% |

+ | EBIT Margin | 4.2% | 1.2% | 4.1% | 3.3% | 2.1% |

+ | Net Margin | 2.7% | 0.4% | 2.8% | 2.2% | 0.9% |

+ | FCF Margin | 3.6% | 1.9% | 1.6% | 3.1% | 0.3% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ *Note on comparability: CVS and Cigna revenue and margins are shaded by low-margin pharmacy/retail throughput (premiums are a minority of revenue for both), so their gross and EBIT margins are not directly comparable to UNH's insurance-plus-Optum structure. CVS's EBIT, EBITDA and net margins are additionally depressed by a non-cash goodwill impairment and are shown as-reported, not normalised. See

+ Read against the two genuine like-for-like insurers, UNH's positioning is respectable but not commanding this year. UNH's EBIT margin sits essentially level with Elevance's and ahead of Humana's, while its EBITDA and net margins edge above Elevance's — the residual advantage attributable largely to Optum's higher-margin services and pharmacy earnings layered on top of a health plan whose underwrit

+ **Historical: UnitedHealth Own 5-Year Progression**

+ | Gross Margin | 24.2% | 24.6% | 24.5% | 22.3% | 18.5% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ UNH's own five-year path is the cleaner story: FY2025's EBIT margin of 4.2% marks a distinct step down from the mid-single-digit levels the company sustained through FY2021–FY2024, consistent with the genuine margin reset documented in Section 3 — a reset driven by the medical-cost step-up and the collapse of favourable prior-year reserve development, not by a one-off. The peer benchmarking should

+ | Metric | UnitedHealth | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | ROIC | 11.3% | 2.9% | 10.3% | 11.3% | 8.8% |

+ | ROE | 12.9% | 2.4% | 12.9% | 14.3% | 6.7% |

+ | ROA | 4.0% | 0.7% | 4.7% | 3.8% | 2.4% |

+ | Asset Turnover | 1.45x | 1.59x | 1.64x | 1.74x | 2.65x |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1. Peer ROIC figures are analyst-computed on a simplified basis; small differences versus UNH's own figure should not be over-read. CVS returns are depressed by a goodwill impairment (see 5.7).*

+ On ROIC, UNH sits at the top of the insurer pack but is no longer the clear cohort leader it was before FY2025: its return is ahead of Humana and Elevance but effectively level with Cigna, which edges it. The vertical-integration premium that Optum's capital-light services and pharmacy earnings historically delivered has been **compressed by the trough, not eliminated** — the advantage survives in

+ The picture is more honest — and less flattering — on the other two metrics. On **ROE**, UNH is only mid-pack: it is roughly level with Elevance and actually trails Cigna, whose lower-capital, PBM-weighted model earns a higher accounting return on equity this year. On **ROA**, UNH again sits behind Elevance. And on **asset turnover**, UNH posts the **lowest** figure in the group by a clear margin

+ **Historical: UnitedHealth Own 5-Year Progression**

+ | ROIC | 20.2% | 21.4% | 21.6% | 18.2% | 11.3% |

+ | ROE | 25.2% | 26.9% | 26.9% | 15.9% | 12.9% |

+ | ROA | 8.4% | 8.8% | 8.6% | 5.0% | 4.0% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ UNH's own history confirms that FY2025 returns are a cyclical low rather than a structural break: ROIC, ROE and ROA all step down into FY2025 from the levels sustained across the prior four years, mirroring the margin reset. A normalised, through-cycle return would sit above the FY2025 print — which is precisely why the valuation in Section 6 does not extrapolate the trough.

+ | Metric | UnitedHealth | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | Net Debt / EBITDA | 2.3x | 6.1x | 2.3x | 2.0x | 2.3x |

+ | Total Debt / Equity | 0.8x | 0.9x | 0.7x | 0.8x | 0.7x |

+ | Interest Coverage | 4.7x | 1.5x | 5.8x | 6.5x | 4.3x |

+ | Current Ratio | 0.8x | 0.8x | 1.5x | 0.8x | 2.0x |

+ | FCF Margin | 3.6% | 1.9% | 1.6% | 3.1% | 0.3% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1. CVS's Net Debt/EBITDA and interest coverage are distorted by the goodwill-impairment-driven collapse in EBITDA and are not representative of underlying leverage (see 5.7).*

+ On leverage, UNH is unremarkable — and that is the correct read, not a criticism. Its Net Debt/EBITDA sits in the middle of the clean comparables, essentially level with Elevance and Humana and modestly above Cigna's lower figure; total debt-to-equity is likewise mid-pack. CVS's apparent 6.1x leverage is an impairment artifact — the denominator has collapsed, not the debt risen — and should be dis

+ The one figure that stands out is UNH's **current ratio**, the lowest in the group. For a managed-care holding company this is largely structural — medical-claims payables and the float dynamics of an insurance book depress the reported current ratio without signalling liquidity stress — but it should be read alongside the parent-company capital constraint documented in Section 3 (upstream subsidi

+ | Metric | UnitedHealth | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ | EV/EBITDA | 18.2x | 19.1x | 11.3x | 8.1x | 15.6x |

+ | P/E | 30.7x | 68.5x | 15.3x | 12.3x | 39.3x |

+ | FCF Yield | 4.4% | 6.4% | 3.7% | 11.4% | 0.8% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ *All peer valuation multiples are market-sourced and computed on FY2025 (trough) earnings, so P/E and EV/EBITDA are elevated across the entire cohort. CVS's 68.5x P/E is a goodwill-impairment artifact, not a valuation signal; Humana's 0.8% FCF yield reflects one-off working-capital timing (see 5.7). Multiples are subject to change with price movements.*

+ This is the table most likely to mislead, and the warning at the top of the section applies most forcefully here. Every P/E and EV/EBITDA multiple shown sits on FY2025 trough earnings, so the whole cohort looks optically expensive. Read naively, the ranking says UNH is among the most expensive names (a premium EV/EBITDA and a 30.7x P/E), while Cigna at 12.3x and Elevance at 15.3x look "cheap." Tha

+ 1. **Cigna's low multiple is a mix artifact.** Its P/E and EV/EBITDA are struck against a large, low-margin pharmacy-services revenue base; the multiple is not comparable to a risk-bearing insurer's and does not make Cigna structurally cheaper than UNH on a quality-adjusted basis.

+ 2. **CVS's high P/E is an impairment artifact.** Its 68.5x figure is the mechanical result of the goodwill write-down crushing the denominator; it is noise, not a rich valuation.

+ 3. **The denominators are cyclically depressed for all of them.** Because FY2025 earnings sit at a cohort-wide trough, every P/E is inflated relative to a normalised figure — so a cross-sectional multiple comparison this year mostly measures who took the biggest earnings hit, not who offers the best value.

+ UNH's premium to Elevance is therefore only partly a "quality premium" for Optum, scale and vertical integration; it is also amplified by UNH absorbing a proportionally large earnings hit into the FY2025 denominator. UNH's FCF yield of 4.4% is the more robust cross-check in the group — cash-based and less distorted by the reserve and impairment noise that corrupts the earnings multiples — and it s

+ **Historical: UnitedHealth EV/EBITDA (period-end price)**

+ | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |

+ |---|---|---|---|---|

+ | 18.8x | 17.2x | 14.9x | 14.6x | 15.5x |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ UNH's own EV/EBITDA history frames the point: the current multiple reflects a compressed EBITDA denominator rather than an expanded valuation, so the "premium" is as much a numerator problem as a price problem. Normalised for the FY2025 trough, UNH's forward valuation is less demanding than the trailing figure implies — the analytical basis for the price target in Section 6.

+ | Metric | UnitedHealth | CVS Health Corporation | Elevance Health, Inc. | The Cigna Group | Humana Inc. |

+ |---|---|---|---|---|---|

+ | Days Sales Outstanding | 19 days | 36 days | 40 days | 38 days | 9 days |

+ | Days Inventory Outstanding | - | 20 days | 0 days | 11 days | 0 days |

+ | Days Payables Outstanding | 36 days | 19 days | 16 days | 16 days | 19 days |

+ | Cash Conversion Cycle | -18 days | 38 days | 24 days | 33 days | -10 days |

+ | CapEx / Revenue | 0.8% | 0.7% | 0.6% | 0.4% | 0.4% |

+ *Source: Peer-company SEC filings; comparability notes in 5.7 — see Appendix A.1.*

+ The working-capital cycle metrics in the first four rows are **not meaningful operating-efficiency signals for these companies**, and should not be read as such. For managed-care businesses, "receivables" are premium and CMS receivables, the largest payables (medical claims and benefits payable, pharmacy claims payable) sit outside the trade-payables line entirely, and only the retail-pharmacy nam

+ The one efficiency row that does carry signal is **CapEx/Revenue**, where all five companies run only minimal physical capital expenditure relative to revenue — confirming the asset-light-at-the-margin nature of the model (the heavy assets are goodwill and acquired businesses, not physical plant). UNH's capital intensity is broadly in line with the group; its differentiation is in what it does wit

+ The tables above are only decision-useful if the reader understands exactly where each peer is **not** a clean comparable. Every material issue below is reflected in the commentary beside the relevant table, not hidden here.

+ - **Sector-wide FY2025 margin trough (affects the entire cohort — the single most important caveat).** FY2025 was an industry-wide managed-care margin shock: elevated Medicare Advantage and Medicaid utilisation lifted every company's medical-loss ratio and compressed every company's margin in the same year. Because the whole group is at a cyclical low simultaneously, the absolute margins, returns

+ - **CVS Health — business mix (revenue, gross/EBIT/EBITDA/net margins).** CVS is a retail-pharmacy, PBM and insurer conglomerate; premiums are only about a third of its revenue, and its "cost of products sold" is real retail and drug cost, structurally different from a health plan's medical cost. Its consolidated single-digit margins are therefore **not** comparable to UNH's insurance-plus-Optum s

+ - **CVS Health — goodwill impairment (EBIT/EBITDA/net margins, ROE, ROA, ROIC, Net Debt/EBITDA, interest coverage, P/E).** CVS's FY2025 operating and net income are depressed by a large non-cash goodwill impairment on its Health Care Benefits reporting unit. All CVS figures are shown **as reported, not normalised**, which mechanically inflates its P/E to 68.5x and its Net Debt/EBITDA to 6.1x, and

+ - **Cigna — PBM-led mix (revenue, gross/EBIT/EBITDA margins, MCR).** Cigna is dominated by Evernorth pharmacy services; pharmacy revenue is the large majority of the total and insurance premiums a small minority. Its thin headline margins reflect low-margin pharmacy pass-through, not weakness versus UNH, and its medical-loss ratio covers only its small insured book — it is not a consolidated manag

+ - **Elevance — the clean comparable (informational).** Elevance is the closest structural match to UnitedHealthcare and the single best like-for-like peer, with clean period and standard alignment. The one nuance: its Carelon services arm is far smaller than UNH's Optum, so where UNH's consolidated economics beat Elevance's, the gap reflects Optum's contribution, not just superior health-plan unde

+ - **Humana — one-off cash-flow distortion (FCF margin, FCF yield).** Humana's FY2025 operating cash flow collapsed from the prior year on working-capital timing (benefits-payable and Medicare-receivable timing) layered on the margin shock, leaving free cash flow — and its 0.8% FCF yield — unusually depressed. This is **not** a normalised run-rate and should not be read as a structural cash-generat

+ - **Working-capital cycle metrics not meaningful (DSO/DIO/DPO/CCC, all peers).** For these insurers, the working-capital cycle metrics are largely uninformative: the largest payables sit outside trade payables, receivables are premium/CMS balances, and only the retail-pharmacy names carry inventory. They are computed for completeness but must not be used to rank operating efficiency — MLR, asset t

+ - **All valuation multiples are market-sourced on trough earnings.** EV/EBITDA, P/E, EV/Revenue and FCF yield are Tier 2 market-sourced, using market capitalisations as of mid-August 2026 and FY2025 primary-filing balance-sheet and earnings inputs. Because the earnings denominators are at a cohort-wide trough, every earnings multiple is elevated; a normalised view requires the forward, through-cyc

+ - **Cross-period comparability — the January 2026 segment realignment.** A further caveat applies across time rather than across peers: effective 1 January 2026 UNH realigned its reporting segments, moving Optum Financial (including Optum Bank) out of Optum Health and into Optum Insight, with prior periods to be recast in 2026 filings. FY2025 figures in this section are on the pre-realignment basi

+ - **CVS sourcing note (auditability).** CVS figures are taken from the CVS FY2025 10-K filed on SEC EDGAR, not the earlier (FY2024) CVS 10-K held in the working folder, to keep the comparison period aligned with UNH's FY2025 and with the Elevance, Cigna and Humana FY2025 filings.

+ We value UnitedHealth on four methods, equal-weighted at 25% each within every scenario, and we lead the reader's attention with the DCF for a specific reason: FY2025 is a dirty trough year, and only an intrinsic model that normalizes earnings can see through it. Reported FY2025 operating income carries a one-time deconsolidation gain booked inside operating costs, a Q4 restructuring charge that p

+ | DCF (3 scenarios) | 25% | Intrinsic value on a normalized, recovering earnings path; the only method that strips the FY2025 one-offs and the lost reserve cushion; most sensitive to the discount rate, which for UNH is the entire debate |

+ | P/E Relative | 25% | Earnings-based and market-oriented, but anchored to a trough GAAP EPS; useful as a sentiment check, not as a normalized anchor |

+ | EV/EBITDA Relative | 25% | Capital-structure-neutral and the sector standard, but UNH's own headline multiple is a trough-EBITDA artifact and the peer cohort is depressed in sympathy |

+ | FCF Yield | 25% | Captures cash-generation quality; a check on whether the intrinsic and multiple approaches are corroborated by the cash the business actually throws off |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ | Scenario | Fair Value / Share | Upside / Downside vs. Current Price ($405.59) |

+ | Bear | $258.80 | Substantial downside vs. $405.59 |

+ | Base | $374.16 | -7.8% |

+ | Bull | $521.23 | Substantial upside vs. $405.59 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ The base-case DCF of $374.16 sits modestly below the current price, an implied downside of -7.8%, and the spread between the bear case of $258.80 and the bull case of $521.23 is the widest we carry on any name in the coverage — the range is not noise, it is the thesis. The single most useful sanity check is the bear-case floor: at $258.80, the bear case sits far below the current price of $405.59,

+ | P/E | 30.7x | 30.0x | $396.90 |

+ | EV/EBITDA | 18.2x | 18.0x | $399.11 |

+ | FCF Yield | 4.4% | 4.5% | $397.97 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ *The current multiple shows where the stock trades today; the target multiple is the analyst's through-cycle anchor; the implied fair value is the target multiple applied to the company's metric. These three relative fair values and the DCF are equal-weighted into the composite (6.4).*

+ The critical judgment in this section is that we did **not** anchor the target multiples to the peer group. The entire managed-care cohort is at a cyclical medical-loss-ratio trough, so peer P/E and EV/EBITDA multiples sit on depressed earnings — CVS's headline P/E is a goodwill-impairment artifact and Humana's is inflated by the same trough dynamic. Applying a distressed peer multiple to UNH's ow

+ | DCF | $258.80 | $374.16 | $521.23 |

+ | P/E Relative | $337.37 | $396.90 | $456.44 |

+ | EV/EBITDA Relative | $328.94 | $399.11 | $469.27 |

+ | FCF Yield | $346.07 | $397.97 | $468.21 |

+ | **Composite Fair Value** | **$317.79** | **$392.03** | **$478.78** |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ **Composite Fair Value (Base):** $392.03

+ **Current Price:** $405.59 | **Implied Upside / Downside:** -3.3%

+ The dispersion between the bear composite of $317.79 and the bull composite of $478.78 is wide, and honesty requires naming its single dominant driver: it is not the operating assumptions, it is the discount rate — specifically, which beta window one believes describes UnitedHealth today. The pre-2025 five-year monthly beta portrays the old, defensive, low-volatility UNH and produces a cost of equ

+ The sensitivity of the base-case DCF fair value to the WACC and the terminal growth rate is shown below. The current share price of $405.59 is implied at approximately the base WACC of 9.4% combined with a terminal growth rate of about 3.5% — that is, one notch of terminal growth above our 3.0% base assumption — or, equivalently, at our 3.0% terminal growth and a WACC modestly below the 24-month-b

+ | WACC (down) / TGR (across) | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |

+ | 8.4% | 389.5 | 420.9 | 458.3 | 503.3 | 558.6 |

+ | 8.9% | 355.4 | 381.7 | 412.6 | 449.3 | 493.4 |

+ | **9.4%** | 325.9 | 348.3 | **374.2** | 404.5 | 440.5 |

+ | 9.9% | 300.2 | 319.3 | 341.3 | 366.7 | 396.5 |

+ | 10.4% | 277.5 | 294.1 | 312.9 | 334.5 | 359.5 |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ **Rating:** HOLD | **12-Month Price Target:** $374.16 | **Conviction:** Medium

+ Our rating is HOLD with a 12-month price target of $374.16 and Medium conviction. The target is anchored to the base-case DCF — the one method that normalizes the trough — with the composite fair value of $392.03 and the bear-to-bull composite range of $317.79 to $478.78 framing the honest bounds around it. We stop at HOLD rather than a directional rating because the position is genuinely two-side

+ The risk pillars of this rating are the six red-flag findings from our forensic review, and none of them is generic to managed care. **First, the favorable prior-year reserve development that had padded earnings collapsed to a fraction of its prior-two-year level while the premium-deficiency reserve was rebuilt.** This is critical to interpret correctly: management did not flex reserves to defend

+ **Fourth, the parent company is under real capital strain, and this is the pillar most readers get wrong because they assume group cash is fungible — it is not.** UnitedHealth is a holding company whose regulated insurance subsidiaries are legally required to hold statutory capital and can upstream cash to the parent only within regulatory limits; that upstream dividend flow is the engine that fun

+ Layered over these company-specific findings are the industry risks that are real but shared: Medicare Advantage rate adequacy and intensifying risk-adjustment scrutiny, the medical-cost-trend cycle that drove the medical care ratio sharply higher, and the reality that the cost pressure is industry-wide rather than a UNH-specific execution failure. We do not treat these as differentiating — but th

+ The two-sidedness is the point of the HOLD. The dominant downside is that the unquantified DOJ and IRS overhangs crystallize while the medical-loss ratio stays elevated and the reserve cushion does not return — in which world the bear composite of $317.79 becomes the reference, not the tail. The symmetric — and, for a HOLD rating, equally important — risk is that we are wrong on the other side: if

+ **Key Catalyst:** A clearing of the risk overhangs — most powerfully a favorable resolution or narrowing of the DOJ Medicare action, combined with demonstrable stabilization in the medical-loss ratio and reserve development — that allows the market to re-rate UNH back toward its pre-shock, defensive risk profile. Because the valuation is dominated by the discount rate, it is the compression of the

+ **Key Risk:** The dominant risk is bimodal and rooted in the discount rate. On the downside, the unquantified and unaccrued DOJ-Medicare and IRS transfer-pricing overhangs crystallize while the medical-cost cycle keeps the loss ratio elevated and Optum Health goodwill comes under impairment pressure — pulling the shares toward the bear composite. On the upside, the same discount-rate mechanism mea

+ | 1 | Risk regime normalizes and the discount rate compresses toward the pre-shock profile | 24-month beta reverts toward the five-year level and/or rating-agency outlooks revised from Negative to Stable | 6–18 months |

+ | 2 | Medical-loss ratio improves durably, confirming the modeled margin recovery | Medical care ratio sustained lower by 150+ bps for two or more consecutive quarters, consistent with the modeled terminal EBITDA-margin recovery path | 2–4 quarters |

+ | 3 | Reserve development stabilizes positively without borrowing from future years | Favorable prior-year development net-positive across three-plus consecutive quarters, not concentrated in a single seasonal release | 3–4 quarters |

+ | 4 | The two largest unquantified overhangs resolve favorably | DOJ Medicare action narrowed/dismissed and/or IRS transfer-pricing NOPAs settled with no material assessment | Event-driven |

+ | 5 | Buybacks resume at the pre-2025 pace funded from upstream dividends, signaling parent liquidity has recovered | Repurchase run-rate restored and funded by regulated-subsidiary dividends rather than debt or forward contracts | 2–4 quarters |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ | 1 | Optum Health goodwill impairment at the next annual test | Any non-cash goodwill impairment recorded at or after the 1 October 2026 test date | Annual test (Q4 2026) |

+ | 2 | Medical-cost trend re-accelerates and the loss ratio deteriorates further | Medical care ratio rises above the FY2025 level for two consecutive quarters | 2 quarters |

+ | 3 | Reserve strengthening or adverse prior-year development | A further premium-deficiency reserve build or unfavorable prior-year development disclosed in any quarter | Quarterly |

+ | 4 | Adverse DOJ or IRS outcome moves from overhang to quantified charge | First material legal accrual or estimable range disclosed, or IRS assessment extended to post-2020 years | Event-driven |

+ | 5 | Capital-return capacity deteriorates as upstream dividends stay constrained | Dividend growth halted or buybacks suspended again, or any rating downgrade off the current Negative outlook | 1–2 quarters |

+ *Source: FL valuation model (Valuation sheet) — see Appendix A.1–A.2.*

+ # Section 7 — Quarterly Update: Q2 2026

+ | **Action** | HOLD — the report-level rating, unchanged by this quarter |

+ | **Reason** | Operating earnings of $7,991.0M (+55.2% YoY, a 7.1% operating margin against 4.6%) are 91.2% operational: only $200M of prior-year reserve development and $49M of loss-contract-reserve release sit inside the $2,841M increase, so the recovery is real — but it is being earned on a book that shrank by 1.6 million people (-3%), the underlying operating margin is 6.9% rather than the 7.6

+ | **Thesis intact?** | PARTIALLY — the operating recovery is confirmed and is higher quality in Q2 2026 than the first-half aggregate suggests, but three things weakened: parent-company cash available for general corporate use is $1.1 billion against $3.5 billion of committed outflows in the first two days after quarter end (10-Q pp. 12, 22–23), 1H operating cash flow of $19,964M rose $7,320M whil

+ | **Trigger to revisit** | Parent-level liquidity. If "cash available for general corporate use" stays at or below $1.1 billion for a third consecutive quarter while medical costs payable continues to decline (down $729M sequentially to $38,930M, with IBNR down to $26.5 billion from $27.6 billion at 31 March 2026), the action moves to REDUCE. A current-accident-year MCR at or below 85.0% for two c

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026; FL valuation model (Valuation sheet) for the fair-value, price and rating references — see Appendix A.1–A.2.*

+ | Metric | Q2 2026 | Q2 2025 | YoY Δ | Q1 2026 | QoQ Δ |

+ | **Revenue ($M)** | $112,032.0M | $111,616.0M | +0.4% | $111,721.0M | +0.3% |

+ | **Gross Profit ($M)** ᵃ | $23,299.0M | $20,012.0M | +16.4% | $25,409.0M | -8.3% |

+ | Gross Margin | 20.8% | 17.9% | +2.9 pp | 22.7% | -1.9 pp |

+ | **EBITDA ($M)** | $9,031.0M | $6,234.0M | +44.9% | $10,019.0M | -9.9% |

+ | EBITDA Margin | 8.1% | 5.6% | +2.5 pp | 9.0% | -0.9 pp |

+ | **EBIT ($M)** | $7,991.0M | $5,150.0M | +55.2% | $8,990.0M | -11.1% |

+ | EBIT Margin | 7.1% | 4.6% | +2.5 pp | 8.0% | -0.9 pp |

+ | **Net Income ($M)** | $5,484.0M | $3,406.0M | +61.0% | $6,280.0M | -12.7% |

+ | Net Margin | 4.9% | 3.1% | +1.8 pp | 5.6% | -0.7 pp |

+ | **Diluted EPS** | $6.04 | $3.74 | +61.5% | $6.90 | -12.5% |

+ YoY Δ is computed as (CQ - PYSQ) / |PYSQ| × 100 — revenue: (112,032 - 111,616) / 111,616 × 100 = +0.4%. QoQ Δ is computed as (CQ - PQ) / |PQ| × 100 — revenue: (112,032 - 111,721) / 111,721 × 100 = +0.3%. Margins are computed as metric / revenue × 100 — gross margin CQ: 23,299 / 112,032 × 100 = 20.8%; EBITDA margin CQ: 9,031 / 112,032 × 100 = 8.1%; EBIT margin CQ: 7,991 / 112,032 × 100 = 7.1%; net

+ ᵃ UnitedHealth Group does not present a gross-profit line. Gross profit here is total revenues less the two direct cost-of-revenue lines — medical costs of $75,358M plus cost of products sold of $13,375M = $88,733.0M in Q2 2026 (Q2 2025: $78,585M + $13,019M = $91,604.0M) — *excluding* the separately reported operating costs line of $14,268.0M and depreciation and amortisation of $1,040.0M. EBIT is

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026 — Condensed Consolidated Statements of Operations (10-Q p. 2); Q1 2026 column from the FL workbook quarterly series (Data sheet, col. 22), which reconciles exactly to the six-month statement less the three-month column (revenue $223,753M - $112,032M = $111,721M; EBIT $16,981M - $7,991M = $8,990M; net earnings **attributable to UnitedHe

+ **Medical care ratio — the ratio that actually governs this business**

+ | Measure | Q2 2026 | Q2 2025 | YoY Δ | Q1 2026 | QoQ Δ |

+ |---|---|---|---|---|---|

+ | Reported MCR (medical costs / premiums) | 86.7% | 89.4% | -2.7 pp | 83.9% ᵇ | +2.8 pp |

+ | Prior-year reserve development ($M, favourable) | (200) | — ᶜ | +200 | (1,050) | -850 |

+ | Premium deficiency / loss-contract reserve release ($M) | (49) | — ᶜ | +49 | (187) | -138 |

+ | **Current-accident-year MCR** ᵈ | **87.0%** | **89.4%** | **-2.4 pp** | **85.3%** | **+1.7 pp** |

+ | Operating margin excluding both reserve items ᵉ | 6.9% | 4.6% | +2.3 pp | 6.9% | -0.0 pp |

+ ᵇ Q1 2026 reported MCR is derived, not printed: (six-month medical costs $148,847M - Q2 $75,358M) / (six-month premiums $174,517M - Q2 $86,956M) = $73,489M / $87,561M = 83.9% (10-Q pp. 2, 18).

+ ᶜ Note 4 discloses prior-year development for the **six months** only. The standalone quarter is derived by differencing this filing's six-month rollforward against the Q1 2026 10-Q's three-month rollforward: prior years $(1,250)M - $(1,050)M = $(200)M in Q2 2026, and premium deficiency/loss-contract reserves $(236)M - $(187)M = $(49)M. On the same basis Q2 2025 is $(320)M - $(320)M = **nil**, and

+ ᵈ Current-accident-year MCR = current-year reported medical costs / premiums, taken directly from Note 4's "Current year" line: Q2 2026 ($150,333M - $74,726M) = $75,607M / $86,956M = 87.0%; Q1 2026 $74,726M / $87,561M = 85.3%; Q2 2025 ($152,316M - $73,731M) = $78,585M / $87,905M = 89.4% (10-Q p. 11; Q1 2026 10-Q p. 11).

+ ᵉ EBIT less both reserve items, over revenue: Q2 2026 ($7,991M - $200M - $49M) / $112,032M = 6.9%; Q1 2026 ($8,990M - $1,050M - $187M) / $111,721M = 6.9%; Q2 2025 $5,150M / $111,616M = 4.6%.

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026 — Note 4, Medical Costs Payable (10-Q p. 11) and Results Summary (10-Q p. 18); standalone-quarter splits derived by differencing against the Form 10-Q for the quarterly period ended 31 March 2026 (10-Q p. 11).*

+ **This is the single most important finding in the section.** The brief on this quarter was that roughly $1.25 billion of favourable prior-year reserve development flattered first-half operating earnings — about 7% of the total. That is arithmetically true: $1,250M against six-month operating earnings of $16,981M is 7.4%, and against the $2,712M six-month increase in operating earnings it is 46.1%

+ **Segment results — under the 1 January 2026 realignment**

+ | Segment | Revenue Q2 2026 ($M) | Revenue Q2 2025 ($M) ᶠ | YoY Δ | Op. Earnings Q2 2026 ($M) | Op. Earnings Q2 2025 ($M) ᶠ | YoY Δ | Op. Margin Q2 2026 | Op. Margin Q2 2025 ᶠ | Δ pp |

+ |---|---|---|---|---|---|---|---|---|---|

+ | UnitedHealthcare | 86,017 | 86,103 | -0.1% | 3,942 | 2,075 | +90.0% | 4.6% | 2.4% | +2.2 pp |

+ | Optum Health | 23,472 | 24,725 | -5.1% | 1,190 | 429 | +177.4% | 5.1% | 1.7% | +3.4 pp |

+ | Optum Insight | 5,402 | 5,232 | +3.2% | 1,369 | 1,205 | +13.6% | 25.3% | 23.0% | +2.3 pp |

+ | Optum Rx | 38,292 | 38,459 | -0.4% | 1,490 | 1,441 | +3.4% | 3.9% | 3.7% | +0.2 pp |

+ | Optum eliminations | (1,503) | (1,191) | +26.2% ᵍ | — | — | — | — | — | — |

+ | Optum (total) | 65,663 | 67,225 | -2.3% | 4,049 | 3,075 | +31.7% | 6.2% | 4.6% | +1.6 pp |

+ | Corporate eliminations | (39,648) | (41,712) | -4.9% ᵍ | — | — | — | — | — | — |

+ | **Consolidated** | **$112,032.0M** | **$111,616.0M** | **+0.4%** | **$7,991.0M** | **$5,150.0M** | **+55.2%** | **7.1%** | **4.6%** | **+2.5 pp** |

+ ᶠ **Prior-period segment amounts have been recast** to reflect the 1 January 2026 realignment moving Optum Financial, including Optum Bank, out of Optum Health and into Optum Insight; the reportable segments themselves are unchanged (10-Q pp. 14–15, footnote (b); MD&A p. 19). **Within this filing the year-on-year comparison is therefore like-for-like — but against any earlier publication it is not

+ ᵍ Eliminations are negative amounts; a positive Δ means a *larger* elimination, not an improvement.

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026 — Note 9, Segment Financial Information (10-Q pp. 14–15) and MD&A reportable segment summary (10-Q p. 20); originally-reported Q2 2025 segment figures from the Form 10-Q for the quarterly period ended 30 June 2025 (p. 20).*

+ UnitedHealthcare contributed $1,867M of the $2,841M group operating-earnings increase (65.7%) and Optum Health $761M (26.8%); together 92.5%. Both are margin recoveries, not growth: UnitedHealthcare revenue fell 0.1% and Optum Health revenue fell 5.1%.

+ **Revenue:** The top line was effectively flat — $112,032.0M against $111,616.0M, +0.4% — because price and mix offset a materially smaller book. UnitedHealthcare served 48,525 thousand medical members against 50,115 thousand, **1,590 thousand fewer people (-3.2%)**, with Medicare Advantage down 785 thousand (-9%), Medicaid down 710 thousand (-9%) and risk-based commercial down 785 thousand (-9%),

+ **Cost and margin:** COGS of $88,733.0M in Q2 2026 versus $91,604.0M in Q2 2025 fell 3.1% against revenue at +0.4%, worth +2.9 pp of gross margin — the whole of it in medical costs, which fell $3,227M (-4%) while cost of products sold rose $356M (+3%) (10-Q p. 18). Management attributes the medical-cost decline to "fewer people served across UnitedHealthcare and Optum Health and favorable prior pe

+ **Below the line:** Interest expense of $962.0M fell 6.3% from $1,027.0M on $4,813M of six-month debt repayment and no commercial paper outstanding, a $65M tailwind partly offset by the loss on sale of subsidiary and subsidiaries held for sale widening to $(61)M from $(41)M on the South American exit (10-Q pp. 2, 6, 11). The effective tax rate rose to 18.6% from 12.5% — a $788M larger provision —

+ | Metric | Q2 2026 | Q2 2025 | YoY Δ | Q1 2026 | QoQ Δ |

+ | Cash ($M) | $28,585.0M | $28,596.0M | -0.04% | $28,001.0M | +2.1% |

+ | Net Debt ($M) | $44,743.0M | $50,597.0M | -11.6% | $49,916.0M | -10.4% |

+ | Net Debt / LTM EBITDA | 1.7× ʰ | — | — | — | — |

+ | Total Assets ($M) | $309,727.0M | $308,573.0M | +0.4% | $312,644.0M | -0.9% |

+ | Equity ($M) ⁱ | $98,447.0M | $94,724.0M | +3.9% | $97,881.0M | +0.6% |

+ | OCF ($M) | $11,052.0M | $7,188.0M | +53.8% | $8,912.0M | +24.0% |

+ | CapEx ($M) ʲ | $799.0M | $886.0M | -9.8% | $763.0M | +4.7% |

+ | FCF ($M) | $10,253.0M | $6,302.0M | +62.7% | $8,149.0M | +25.8% |

+ | Dividends Paid ($M) ʲ | $2,087.0M | $2,000.0M | +4.4% | $2,005.0M | +4.1% |

+ YoY and QoQ percentages use the same formulas as 7.1 — net debt YoY: (44,743 - 50,597) / |50,597| × 100 = -11.6%; net debt QoQ: (44,743 - 49,916) / |49,916| × 100 = -10.4%.

+ ʰ *Net Debt / LTM EBITDA: LTM EBITDA = Q3 2025 $5,414.0M + Q4 2025 $1,497.0M + Q1 2026 $10,019.0M + Q2 2026 $9,031.0M = $25,961.0M (the two 2025 quarters are taken from the workbook's standalone quarterly series, Data sheet row 20, cols 20–21, because the section-7 data pack carries only the CQ/PYSQ/PQ columns). Net Debt $44,743.0M / $25,961.0M = **1.7×**. This ratio is flattered downward by nothi

+ ⁱ Equity here is the parent-only basis used throughout this report: total equity of $104,513M less nonredeemable noncontrolling interests of $6,066M = $98,447.0M (10-Q p. 1). Redeemable noncontrolling interests of $1,436M sit outside equity in the mezzanine and are excluded from both.

+ ʲ CapEx and dividends are stored as positive magnitudes in the workbook and shown as such here; both are cash **outflows**. A positive Δ therefore means a larger outflow. Both tie to the filing: six-month capex of $1,562M = $799.0M + $763.0M, and the two 2026 dividend payments of $2,005M on 17 March and $2,087M on 23 June (10-Q pp. 6, 12).

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026 — Condensed Consolidated Balance Sheets (10-Q p. 1) and Condensed Consolidated Statements of Cash Flows (10-Q p. 6); standalone-quarter cash-flow figures derived by the pipeline from the six-month statement less the prior 10-Q's three-month statement.*

+ **Balance sheet note:** The material movement is deleveraging paid for out of the investment and receivables book rather than out of retained cash: total debt fell to $73,328M from $78,389M at 31 December 2025 after $2,500M of long-term repayments and $2,313M of net short-term repayments, with no commercial paper outstanding at 30 June 2026, while cash rose to $28,585.0M from $24,365M — net debt d

+ **Cash flow note:** FCF conversion = FCF / Net Income = $10,253.0M / $5,484.0M = **187.0%** in Q2 2026, against 185.0% in Q2 2025 and 129.8% in Q1 2026 — but the six-month composition disqualifies the headline as evidence of earnings quality. Six-month operating cash flow rose $7,320M to $19,964M while **total net earnings including noncontrolling interests** — the line the cash-flow statement ope

+ *Page references are the printed page numbers of the Form 10-Q for the quarterly period ended 30 June 2026. All nine notes were read in full in this session, together with the four primary statements, the whole of Item 2 (MD&A), Item 3, Item 4 and Part II Items 1, 1A, 2, 5 and 6. Comparisons against the prior-year and prior-sequential periods were made by reading the corresponding notes in the For

+ **Note 1 — Basis of Presentation (10-Q pp. 7–8)**

+ Consolidation basis is unchanged: UnitedHealth Group and its subsidiaries including variable interest entities, intercompany accounts and transactions eliminated; the year-end balance sheet derived from audited statements. The note restates that the most significant estimates are **medical costs payable and goodwill** and that "the impact of any change in estimates is included in earnings in the p

+ **Note 2 — Investments (10-Q pp. 8–9)**

+ Total debt securities of $52,545M at amortised cost carry a fair value of $50,757M, with gross unrealised losses of $1,897M against gross gains of $109M. Available-for-sale gross unrealised losses **widened to $1,893M from $1,625M at 31 December 2025**, with $1,638M of that in positions held twelve months or longer, and 31,000 of 42,000 positions in an unrealised loss position. Equity securities w

+ **Note 3 — Fair Value (10-Q pp. 10–11)**

+ Assets at fair value on a recurring basis total $81,875M — 25% Level 1, 73% Level 2, 2% Level 3 — with **no transfers in or out of Level 3 during the six months ended 30 June 2026 or 2025**. Level 3 holdings of $1,375M ($500M corporate obligations, $76M equity securities, $799M loan receivables) are essentially unchanged from $1,372M at year-end. Two disclosures matter analytically. First, **the L

+ **Note 4 — Medical Costs Payable (10-Q p. 11)**

+ The most important note in the filing, treated in full in 7.1 above. Six-month reported medical costs of $148,847M comprise $150,333M of current-year costs, **$(1,250)M of favourable prior-years' development** and $(236)M of changes in premium deficiency and loss contract reserves. The prior-year comparison is $(320)M of development and nil loss-contract movement on $152,316M of current-year costs

+ **Note 5 — Short-Term Borrowings and Long-Term Debt (10-Q p. 11)**

+ The entire note is two sentences: **"As of June 30, 2026, the Company had no commercial paper outstanding,"** with everything else incorporated by reference to Note 8 of the 2025 Form 10-K. **No covenant level and no actual ratio is disclosed in this filing** — MD&A adds only that "as of June 30, 2026, we were in compliance with the various covenants under our bank credit facilities" (10-Q p. 23),

+ **Note 6 — Shareholders' Equity (10-Q pp. 11–12)**

+ Three disclosures, all material. (i) **Dividend:** in June 2026 the Board raised the quarterly dividend to an annual rate of **$9.28 from $8.84** — a 5.0% increase — with payments of $2.21 per share ($2,005M) on 17 March and $2.32 per share ($2,087M) on 23 June 2026, against $4.31 per share and $3,912M for the prior-year six months. **Changed vs. Q2 2025: increased, and this is the first capital-r

+ **Note 7 — Commitments and Contingencies (10-Q pp. 12–13)** — see also the dedicated litigation entry below

+ Beyond legal matters the note discloses one quantified commitment: a first-quarter-2026 agreement to acquire a health-care company for **$3.0 billion**, completed on **2 July 2026 for $1.5 billion in cash with the remaining $1.5 billion payable within one year**. The counterparty is not named and no segment allocation is given. Read against Note 6's $2.0 billion forward settlement on 1 July, the c

+ **Note 8 — Held for Sale and Dispositions (10-Q p. 13)**

+ The remaining South American operations, agreed for sale in Q4 2025, are expected to close in the second half of 2026. Held-for-sale disposal groups carry total assets of $1,039M (South America) and $912M (other businesses) against total liabilities of $986M and $730M — **after remeasurement write-downs to fair value less cost to sell of $(1,656)M and $(561)M respectively, $2,217M in total**, incl

+ **Note 9 — Segment Financial Information (10-Q pp. 14–15)**

+ Four reportable segments, unchanged. The **1 January 2026 realignment** moved Optum Financial including Optum Bank from Optum Health to Optum Insight, with **prior-period segment information recast** — treated in full in 7.1, including the $207M of quarterly operating earnings and $480M of quarterly revenue that moved, and the resulting break with any pre-2026 segment publication. The note also di

+ **Related-party transactions (10-Q pp. 1–2, 4–7, 9, 12–13)**

+ UnitedHealth Group has **no controlling shareholder and this 10-Q contains no related-party transactions note**, consistent with the full-footnote read of the 2025 Form 10-K. This is documented rather than assumed: Note 1's consolidation policy states only that the statements include UnitedHealth Group and its subsidiaries including variable interest entities with intercompany accounts and transac

+ | Relationship | Q2 2026 | Q2 2025 | Change | Source |

+ |---|---|---|---|---|

+ | Earnings attributable to noncontrolling interests | $186M | $166M | +12.0% | 10-Q p. 2 |

+ | Distributions to nonredeemable noncontrolling interests | $179M | $158M | +13.3% | 10-Q p. 4 |

+ | Acquisition and other adjustments of nonredeemable NCI | +$63M | $(19)M | +$82M | 10-Q p. 4 |

+ | Redeemable NCI fair-value and other adjustments | +$16M | $(10)M | +$26M | 10-Q p. 4 |

+ | Nonredeemable NCI balance | $6,066M | $5,745M | +5.6% | 10-Q pp. 1, 4 |

+ | Redeemable NCI balance (mezzanine) | $1,436M | $4,315M | **-66.7%** | 10-Q p. 1; Q2 2025 10-Q p. 1 |

+ | Equity-method investments | $4.0bn | $3.8bn (31 Dec 2025) | +5.3% | 10-Q p. 9 |

+ | Contribution to the United Health Foundation | nil in Q2 2026; **$400M in Q1 2026** | nil | +$400M YTD | 10-Q p. 8 |

+ | Forward-repurchase counterparty — shares held on the company's behalf | 6.4M shares at $312.73 avg; **$2.0bn liability at 30 June 2026, settled 1 July 2026** | none disclosed | new | 10-Q p. 12 |

+ *Source: Form 10-Q for the quarterly period ended 30 June 2026 — Condensed Consolidated Balance Sheets (p. 1), Statements of Operations (p. 2), Statements of Changes in Equity (pp. 4–5), Note 1 (p. 8), Note 2 (p. 9) and Note 6 (p. 12); Q2 2025 comparatives from the Form 10-Q for the quarterly period ended 30 June 2025.*

+ **No terms changed, because there are no related-party terms to change.** The two items that warrant attention are not related-party transactions in the technical sense but function economically as such: the **United Health Foundation**, a company-affiliated charitable entity that received $400 million of disposal proceeds in Q1 2026 — a discretionary transfer of shareholder cash out of the group

+ **Contingencies and litigation (10-Q pp. 12–13, 26)**

+ 1. **DOJ False Claims Act action on Medicare risk-adjustment coding (the 2011 whistleblower case).** The DOJ announced on 14 February 2017 that it would pursue certain claims; in March 2025 a court-appointed Special Master recommended summary judgment **in the company's favour on all remaining claims**; in April 2025 the DOJ moved to reject that report. **The company "cannot reasonably estimate th

+ 2. **IRS transfer-pricing Notices of Proposed Adjustment.** On 6 March 2026 the company received NOPAs for the **2017 through 2020 tax years involving intercompany transfer pricing with a foreign subsidiary**; the IRS "is seeking to significantly increase taxable income for each of the applicable periods and could also seek similar adjustments for subsequent years after 2020." The company disagree

+ 3. **Government investigations, audits and reviews.** The company lists CMS, state insurance departments, state attorneys general, the OIG, OPM, the Office for Civil Rights, the GAO, the FTC, Congressional committees, the DOJ, the SEC, the IRS, the DEA, the Department of Labor, the FDIC, the CFPB, the Defense Contract Audit Agency and the FDA, plus foreign regulators, and states it "has also been

+ 4. **Ordinary-course legal actions** — class actions and suits by members, care providers, consumer advocacy organisations, customers, shareholders and regulators, covering medical malpractice, employment, intellectual property, antitrust, privacy and contract claims. The company records liabilities "where appropriate" but states it "is often unable to estimate the losses or ranges of losses." No

+ 5. **Pending acquisition consideration** — $1.5 billion payable within one year following the 2 July 2026 completion (10-Q p. 12). A firm, dated obligation rather than a contingency.

+ Part II Item 1 adds nothing beyond Note 7, and Item 1A states there have been **"no material changes to the risk factors as disclosed in our 2025 10-K"** (10-Q p. 26) — so Section 2 remains the operative risk register in full. Item 4 concludes that disclosure controls were effective at 30 June 2026 and that there were **no changes in internal control over financial reporting during the quarter** (

+ **Subsequent events (10-Q pp. 12, 23, 26 — there is no dedicated subsequent-events note)**

+ The notes run 1 through 9 and end with segment information (10-Q p. 15); no subsequent-events note exists in this filing. The post-quarter facts the filing does disclose are: (i) **settlement of the $2.0 billion forward share repurchase liability on 1 July 2026** (10-Q p. 12); (ii) **completion on 2 July 2026 of the $3.0 billion health-care acquisition, $1.5 billion paid in cash with $1.5 billion

+ **Guidance status (10-Q pp. 16–24 — none given)**

+ **This Form 10-Q contains no financial guidance of any kind.** There is no revenue, earnings-per-share, medical-cost-ratio or operating-margin outlook anywhere in Item 2; the Executive Overview lists five backward-looking bullets only (10-Q p. 18), and the Forward-Looking Statements section is a generic risk enumeration (10-Q p. 24). The company withdrew guidance during 2025 and this filing does n

+ - **The reserve contribution to the recovery is real but front-loaded into Q1 — and this quarter is cleaner than the first half suggests.** Of the $1,250M of favourable prior-year development recognised in the six months, **$1,050M (84.0%) landed in Q1 2026 and only $200M in Q2 2026** (derived from Note 4 against the Q1 2026 10-Q, 10-Q p. 11). Including the $49M loss-contract release, reserve item

+ - **The MCR improvement survives the same test.** Reported MCR of 86.7% against 89.4% is a 2.7 pp gain; on the current-accident-year basis, which excludes all prior-year development, it is 87.0% against 89.4% — **2.4 pp, or 89% of the reported gain, is genuine** (10-Q pp. 11, 18). Management attributes it to "favorable prior period reserve development, affordability and medical cost management ini

+ - **The recovery is entirely margin, on a shrinking book.** Revenue grew 0.4% while UnitedHealthcare served **1,590 thousand fewer people (-3.2%)** — Medicare Advantage -785 thousand, Medicaid -710 thousand, risk-based commercial -785 thousand — and Optum Rx filled 387 million adjusted scripts against 414 million (-6.5%) (10-Q p. 21). Premiums *fell* $949M; all of the revenue increase came from se

+ - **Parent-company liquidity is the sharpest new risk, and it is quantified.** Of $28,585.0M of consolidated cash, only **$1.1 billion was "available for general corporate use"** at 30 June 2026 — unchanged from 31 March 2026 but **down from $3.3 billion at 30 June 2025, a 66.7% decline** (10-Q p. 22; Q1 2026 10-Q p. 22; Q2 2025 10-Q p. 22). Against that $1.1 billion the company committed **$3.5 b

+ - **Buybacks resumed decisively — and $2.0 billion of them were financed past the balance-sheet date.** The company repurchased **8.7 million shares at an average price of $355.37 in the quarter** (2.0 million at $303.59 in April, 5.0 million at $358.57 in May, 1.7 million at $405.41 in June), against a Q4 2025 halt (10-Q p. 26). But the accounting and the cash diverge: $3,232M of repurchases in t

+ - **Operating cash flow of $19,964M for the six months is up $7,320M on total net earnings including noncontrolling interests up only $2,105M, and the gap is not earnings conversion.** (Total net earnings is the basis the cash-flow statement opens from, $12,151M; the figure attributable to UnitedHealth Group common shareholders is $11,764M, up $2,066M, the $387M difference being the noncontrolling

+ - **The segment realignment makes Optum Health's turnaround look larger than it is.** Prior periods were properly recast (10-Q pp. 14–15), so the comparison *inside this filing* is clean — but the recast cut Optum Health's Q2 2025 operating-earnings base from the **$636M originally published to $429M** by moving Optum Financial and Optum Bank (roughly $480M of quarterly revenue at a ~43% operating

+ - **Deleveraging is genuine: net debt fell 11.6% year on year to $44,743.0M, 1.7× LTM EBITDA and 1.2× on the 2026 run-rate.** The company repaid $2,500M of long-term debt and $2,313M of short-term borrowings net, had no commercial paper outstanding, and issued nothing — a $6,379M swing from the prior-year period's net issuance (10-Q pp. 6, 11). Debt fair value sits $4,282M below carrying value (10

+ - **Goodwill of $110,645M is now 112.4% of shareholders' equity, with no interim impairment test disclosed and the realignment having stripped a ~43%-margin business out of the highest-goodwill reporting unit.** Goodwill plus intangibles of $130,394M is 42.1% of total assets (10-Q p. 1). The filing names goodwill one of only two critical accounting estimates (10-Q p. 24) and then discloses nothing

+ - **Two open matters produced no update, and in one case that is the story.** The DOJ Medicare risk-adjustment action carries **wording identical to the Q1 2026 and Q2 2025 filings**, with the DOJ's motion to reject the Special Master's favourable report pending for sixteen months, no accrual and no estimable range (10-Q p. 13). The IRS transfer-pricing NOPAs for 2017–2020, first disclosed in Q1 2

+ - **The exit from South America is still unfinished and still costing money.** Held-for-sale groups carry $2,217M of cumulative remeasurement write-downs, including $893M of cumulative FX translation losses; the loss on sale widened to $(61)M this quarter from $(41)M, and $(133)M for the six months from $(56)M; roughly $1.95 billion of assets remain to be sold into a second-half 2026 close (10-Q p

+ - **No guidance was restored.** The filing contains no revenue, EPS, MCR or margin outlook of any kind, eighteen months after the 2025 withdrawal (10-Q pp. 16–24).

+ The quarter confirms the recovery thesis on the metric that matters and does not change the report-level call, because the price already reflects it. Operating earnings of $7,991.0M and a 7.1% operating margin against 4.6% are, on examination, 91.2% operational: only $200M of prior-year reserve development and $49M of loss-contract release sit inside the $2,841M increase, and the current-accident-

+ - **Upgrade condition (ADD):** a current-accident-year MCR at or below 85.0% for two consecutive quarters on a stabilised or growing membership base — that is, the 87.0% delivered here improving by 2.0 pp without reserve assistance while UnitedHealthcare stops shedding 1,590 thousand members a year — together with parent cash available for general corporate use recovering above the $3.3 billion of

+ - **Downgrade condition (REDUCE or SELL):** parent cash available for general corporate use remaining at or below $1.1 billion for a third consecutive quarter while medical costs payable continues its sequential decline (down $729M to $38,930M this quarter, IBNR down to $26.5 billion from $27.6 billion at 31 March 2026); or a reversal to net *unfavourable* prior-year development in any quarter; or